JP2024539650A5 - - Google Patents

Info

Publication number
JP2024539650A5
JP2024539650A5 JP2024522466A JP2024522466A JP2024539650A5 JP 2024539650 A5 JP2024539650 A5 JP 2024539650A5 JP 2024522466 A JP2024522466 A JP 2024522466A JP 2024522466 A JP2024522466 A JP 2024522466A JP 2024539650 A5 JP2024539650 A5 JP 2024539650A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
complex according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539650A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078157 external-priority patent/WO2023064927A1/en
Publication of JP2024539650A publication Critical patent/JP2024539650A/ja
Publication of JP2024539650A5 publication Critical patent/JP2024539650A5/ja
Pending legal-status Critical Current

Links

JP2024522466A 2021-10-15 2022-10-14 活性化可能なポリペプチド複合体 Pending JP2024539650A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256410P 2021-10-15 2021-10-15
US63/256,410 2021-10-15
US202263370895P 2022-08-09 2022-08-09
US63/370,895 2022-08-09
PCT/US2022/078157 WO2023064927A1 (en) 2021-10-15 2022-10-14 Activatable polypeptide complex

Publications (2)

Publication Number Publication Date
JP2024539650A JP2024539650A (ja) 2024-10-29
JP2024539650A5 true JP2024539650A5 (cg-RX-API-DMAC7.html) 2025-10-22

Family

ID=84331755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522466A Pending JP2024539650A (ja) 2021-10-15 2022-10-14 活性化可能なポリペプチド複合体

Country Status (17)

Country Link
US (1) US20230183382A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539650A (cg-RX-API-DMAC7.html)
KR (1) KR20240115809A (cg-RX-API-DMAC7.html)
CN (1) CN118103405A (cg-RX-API-DMAC7.html)
AU (1) AU2022365116A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234609A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006111A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240204A (cg-RX-API-DMAC7.html)
IL (1) IL312145A (cg-RX-API-DMAC7.html)
JO (1) JOP20240086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004563A (cg-RX-API-DMAC7.html)
PE (1) PE20241343A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330611A (cg-RX-API-DMAC7.html)
UY (1) UY39984A (cg-RX-API-DMAC7.html)
WO (1) WO2023064927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4496816A1 (en) * 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Egfrviii及cd3抗體構築體
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP4126248A4 (en) * 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2024538141A5 (cg-RX-API-DMAC7.html)
JP2022065174A5 (cg-RX-API-DMAC7.html)
RU2598248C2 (ru) Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
JP2024510098A5 (cg-RX-API-DMAC7.html)
JP2023511376A5 (cg-RX-API-DMAC7.html)
JP2020516287A5 (cg-RX-API-DMAC7.html)
JP2021098732A5 (cg-RX-API-DMAC7.html)
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
JP2023178323A5 (cg-RX-API-DMAC7.html)
JP2024532485A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2021525530A5 (cg-RX-API-DMAC7.html)
JP2023506750A5 (cg-RX-API-DMAC7.html)
JP2022551081A5 (cg-RX-API-DMAC7.html)
US20040220388A1 (en) Novel heterodimeric fusion proteins
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
CN1380341A (zh) 环状单链三特异抗体
JP2025508316A5 (cg-RX-API-DMAC7.html)
JP2020536549A5 (cg-RX-API-DMAC7.html)
JP2025504909A5 (cg-RX-API-DMAC7.html)
JP2020515277A5 (cg-RX-API-DMAC7.html)
JP2023538366A5 (cg-RX-API-DMAC7.html)
CN112111012A (zh) 共价多特异性抗体